These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8171303)

  • 1. Assessing the cost-effectiveness of medical treatments in acid-related diseases. The Markov chain approach applied to a comparison between intermittent and maintenance treatment of reflux esophagitis.
    Stålhammar NO
    Scand J Gastroenterol Suppl; 1993; 199():8-13. PubMed ID: 8171303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation in gastrointestinal disease.
    Jönsson B; Karlsson G
    Scand J Gastroenterol Suppl; 1996; 220():44-51. PubMed ID: 8898435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of the cost-efficacy ratio of omeprazole and ranitidine in the treatment of reflux esophagitis].
    Bergmann JF; Hamelin B; Barbier JP
    Gastroenterol Clin Biol; 1995 May; 19(5):482-6. PubMed ID: 7589999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical or surgical therapy for erosive reflux esophagitis: cost-utility analysis using a Markov model.
    Romagnuolo J; Meier MA; Sadowski DC
    Ann Surg; 2002 Aug; 236(2):191-202. PubMed ID: 12170024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
    Harris RA; Kuppermann M; Richter JE
    Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan.
    Habu Y; Maeda K; Kusuda T; Yoshino T; Shio S; Yamazaki M; Hayakumo T; Hayashi K; Watanabe Y; Kawai K
    J Gastroenterol; 2005 Nov; 40(11):1029-35. PubMed ID: 16322946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
    Barradell LB; McTavish D
    Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPIs vs H2RAs for erosive reflux esophagitis.
    King VJ
    J Fam Pract; 1998 Mar; 46(3):199-200. PubMed ID: 9519012
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis.
    Dean BB; Siddique RM; Yamashita BD; Bhattacharjya AS; Ofman JJ
    Am J Health Syst Pharm; 2001 Jul; 58(14):1338-46. PubMed ID: 11471482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis.
    Ofman JJ; Yamashita BD; Siddique RM; Larson LR; Willian MK
    Am J Manag Care; 2000 Aug; 6(8):905-16. PubMed ID: 11186502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
    Habu Y; Oyasu K; Wakamatsu T; Sumitomo Y; Kiyota K; Inokuchi H; Kawai K
    Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition.
    Harris RA; Kuppermann M; Richter JE
    Am J Med; 1997 Jan; 102(1):78-88. PubMed ID: 9209204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable?
    Boccia G; Manguso F; Miele E; Buonavolontà R; Staiano A
    Am J Gastroenterol; 2007 Jun; 102(6):1291-7. PubMed ID: 17319927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK.
    Wahlqvist P; Junghard O; Higgins A; Green J
    Pharmacoeconomics; 2002; 20(4):279-87. PubMed ID: 11950384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of five maintenance therapies for reflux esophagitis.
    Vigneri S; Termini R; Leandro G; Badalamenti S; Pantalena M; Savarino V; Di Mario F; Battaglia G; Mela GS; Pilotto A
    N Engl J Med; 1995 Oct; 333(17):1106-10. PubMed ID: 7565948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Omeprazole is more cost-effective than ranitidine in reflux esophagitis].
    Lindberg G; Jönsson B
    Lakartidningen; 1992 Jul; 89(30-31):2530-3. PubMed ID: 1507987
    [No Abstract]   [Full Text] [Related]  

  • 17. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
    Festen HP; Schenk E; Tan G; Snel P; Nelis F
    Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease.
    Stålhammar NO; Carlsson J; Peacock R; Müller-Lissner S; Bigard MA; Porro GB; Ponce J; Hosie J; Scott M; Weir DG; Fulton C; Gillon K; Bardhan KD
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):483-97. PubMed ID: 10662395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group.
    Hallerbäck B; Unge P; Carling L; Edwin B; Glise H; Havu N; Lyrenäs E; Lundberg K
    Gastroenterology; 1994 Nov; 107(5):1305-11. PubMed ID: 7926494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life and cost of therapy in reflux disease.
    Glise H
    Scand J Gastroenterol Suppl; 1995; 210():38-42. PubMed ID: 8578204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.